UroPartners is committed to driving innovation through high‑quality clinical research. Here, patients can learn about ongoing and upcoming clinical trials designed to improve outcomes, expand treatment options, and advance the field of urology.
High risk non-muscle invasive bladder cancer with stage TA/CIS- BCG exposed patients to receive instillation of Cretostimogene Grenadenorepvec
Patients with non-muscle invasive bladder cancer unresponsive to BCG to receive instillation of Cretostimogene Grenadenorepvec
Metastatic Castrate Resistant Prostate Cancer Patients Treatment With standard of care Provenge vs additional Provenge Booster dose
Prostate Cancer-Blood/serum sample collection for patients on active surveillance or prostate cancer with a PSA 4.0 or below.
PSMA/PET scan combined with MRI scan in comparison to standard of care for the detection of prostate cancer.
Patients with Intermediate Risk non-muscle invasive bladder cancer receiving instillation of Nadofaragene Firadenovec vs. Observation
Bladder Cancer-An expanded access program allowing patients to receive BCG per standard of care guidelines.
Patients with Intermediate Risk NMIBC with low grade FGFR testing to receive injection of TYRA- 300. Patients need tissue testing for FGFR mutation before TURBT.
Patients with suspected prostate cancer and or T1c tumor stage- undergoing trans perineal prostate biopsy for the indication of a new specimen tissue retrieval method.
Prostate Cancer- AZD5305 in Combination with Physician's Choice New Hormonal Agents in Participants with Metastatic Castration-Sensitive Prostate Cancer with and without HRRm (D9723C00001 - EvoPAR-Prostate 01)
Bladder Cancer- Study of Cretostimogene grenadenorepvec after TURBT vs TURBT for Intermediate-Risk NMIBC
Patients being treated with ORGOVYX for real world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer.
Confirm mdx® for Prostate Cancer Decision on patients
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
